Podcasts about ischemic

Commentary by Dr.  Shinya Goto.

Commentary by Dr. Jian'an Wang.

In this episode, we review the high-yield topic ⁠⁠⁠⁠Ischemic Colitis ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Gastrointestinal section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Very Long-Term Outcomes of Cardiac Resynchronization Therapy in Patients With Ischemic and Nonischemic Cardiomyopathy.

Lancet 1999;353:2001-07Background: Beta-blockers directly reduce cardiac contractility and myocardial oxygen demand. For decades, they were avoided in patients with acute and chronic heart failure over concerns they would facilitate decompensation of the condition. The therapeutic cornerstones of treatment, prior to the modern era of clinical trials, focused on managing symptoms and quality of life with diuretics and inotropic agents like digoxin; however, new paradigms were arising that focused on addressing neurohormonal mechanisms of chronic disease that were over-activated in the failing heart. The first major success came with inhibition of the renin angiotensin aldosterone system with angiotensin converting enzyme inhibitors whose effect on mortality for patients with mild and severe forms of chronic heart failure were demonstrated in the V-HEFT II, CONSENSUS, and SOLVD trials. Additional benefits were demonstrated with the mineralocorticoid receptor antagonist spironolactone in the RALES trial. These drug classes primarily work by reducing afterload and volume retention. Appreciating why they work for improving cardiac performance and managing symptoms in heart failure patients is straightforward when we consider the major factors that effect cardiac stroke volume - preload, afterload and contractility; however, it is also noteworthy the effects these agents have on sudden death. How beta-blockade benefits the failing heart is less obvious (outside prevention of sudden death). Mechanistic studies in patients with chronic heart failure have consistently shown that when beta blockers are used for more than 1 month, left ventricular function improves. Beta blocker therapy appears to restore the density of beta-adrenergic receptors after they have been downregulated by the chronic overactivity of the sympathetic nervous system. The first major placebo-controlled RCT to demonstrate a mortality benefit used the non-selective beta blocker carvedilol. The trial was small and not originally designed to test mortality and was stopped early without clearly predefined stopping rules. Furthermore, 8% of total patients selected for participation in the trial were excluded prior to randomization after a 2 week, open-label run-in phase with the study drug, which saw 2% of all patients experience worsening heart failure or death representing 24 patients (the difference in total deaths between groups was 9 when the trial was stopped). The Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) was the first large scale trial designed to test the hypothesis that beta-blockade with metoprolol controlled/extended release (CR/XL) added to optimum medical therapy reduces mortality in patients with chronic systolic heart failure.Patients: Patients were recruited from 313 sites in 13 European countries and the United States. Eligible patients were men and women between the age of 40 to 80 years with symptomatic heart failure (NYHA class II-IV) for >/= 3 months before randomization. They had to be on a diuretic and ACE inhibitor for at least 2 weeks. Other drugs, including digoxin, could also be used. Patients also had to have an EF of /=68 beats per minute.Patients were excluded if: they had an MI or unstable angina within 28 days; had an indication or contraindication for treatment with beta-blocker; beta blockade within 6 weeks; heart failure due to systemic disease (i.e., amyloidosis) or alcohol abuse; scheduled or performed cardiac transplant; an ICD; procedures such as CABG or PCI planned or performed in the past 4 months; 2nd or 3rd degree AV block unless a pacemaker was present; unstable or decompensated heart failure defined by pulmonary edema or hypoperfusion or supine systolic BP 25% deviation of the number of observed versus expected consumed placebo tablets during the run-in period.Baseline characteristics: The mean age of patients was 64 years and approximately 78% were male. Slightly more than 30% of patients were above the age of 70. The average EF was 28%. The average SBP was 130 mmHg and heart rate was 82 bpm. Most patients had mild to moderate heart failure, with 41% in NYHA Class II, 56% in Class III, and only 3% in Class IV. Ischemic cardiomyopathy accounted for 65% of cases and nonischemic causes accounted for 35%. Most patients were on an ACE inhibitor or ARB (95%) and diuretic (90%). Digoxin was used in 63%. Trial procedures: Prior to randomization, the study was preceded by a single-blind, 2-week placebo run-in period. Patients meeting eligibility were then randomized to placebo or metoprolol CR/XL. The starting dose of placebo or metoprolol CR/XL was 12.5 mg daily for patients in NYHA class III or IV and 25 mg daily for patients in NYHA class II. The dose was doubled every 2 weeks until the target dose of 200 mg daily was reached. Patients were followed every 3 months.Endpoints: The primary outcome was all-cause mortality. It was estimated that 3,200 patients would need to be followed for 2.4 years to detect a 30% relative reduction in mortality based on annual mortality rate of 9.4% in the placebo group. This would achieve at least 80% power with a 2-sided alpha of 0.04. Patients were recruited faster then planned and so the final sample size of 3,991 patients increased the power of the study.The study was monitored by an independent safety committee and predefined stopping rules for efficacy were based on all-cause mortality, done when 25%, 50%, and 75% of expected deaths had occurred. Results: The trial was stopped early after the 2nd preplanned interim analysis when 50% of expected deaths had occurred. The mean duration of follow-up at the time of stopping was 1 year. The mean daily dose of metoprolol CR/XL was 159 mg once daily, with 87% receiving 100 mg or more and 64% receiving the target dose of 200 mg daily. In the placebo group, the corresponding values were 179 mg daily, 91% and 82%. The study drug was discontinued permanently in 14% of patients in the metoprolol group and 15% in the placebo group. Six months after randomization, heart rate decreased by 14 bpm in the metoprolol group compared to only 3 bpm in the placebo group. Systolic blood pressure decreased less in the metoprolol group (-2.1 vs 3.5 mmHg).Compared to placebo, metoprolol significantly reduced all-cause mortality (7.3% vs 10.8%; RR 0.66; 95% CI 0.53—0.81). Cardiovascular mortality accounted for 91% of all deaths; with sudden death accounting for 58% and death from worsening heart failure accounting for 24% of all deaths. All 3 of these causes of death were significantly reduced by metoprolol. The relative and absolute effects on death were greatest for patients with NYHA class III heart failure.Conclusions: In this trial of stable patients with mild to moderate chronic systolic heart failure, who were optimized on an ACEi or ARB and diuretic, metoprolol CR/XL significantly reduced all-cause mortality. Approximately 30 patients would need to be treated with metoprolol compared to placebo for 1 year to prevent 1 death. This trial represents a significant win for beta blockade in patients with chronic systolic heart failure. While the NNT in this trial is slightly higher than in SOLVD, it is important to appreciate that follow-up time in SOLVD was more than 3x longer. Limitations to external validity in this trial include the run-in period and stringent inclusion and exclusion criteria. Our enthusiasm is also tempered by early stopping, which has been found to be associated with false positive or exaggerated results but this concern is mitigated to some extent in this trial because the rules for early stopping were clearly defined in the protocol.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber. Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Clopidogrel Versus Aspirin for Long-term Maintenance Monotherapy in Patients with High Ischemic Risk After Percutaneous Coronary Intervention

In this powerful episode honoring HIE Awareness Month, Neonatal Nurse Practitioner Jessica Fulton shares the raw and emotional story of her son Bo's birth — a delivery marked by unexpected complications that led to a diagnosis of Hypoxic-Ischemic Encephalopathy (HIE). Jessica opens up about what it was like to watch her own son become a critical patient in the very NICU where she had worked for years — as her personal and professional worlds suddenly collided. She speaks candidly about the shocking helplessness she felt as a parent, despite her medical background, and the lifelong challenges that continue to follow: a cerebral palsy diagnosis, fierce advocacy, intensive therapies, emotional isolation, and the realities of parenting a child with complex needs. This episode is a must-listen for NICU parents, healthcare providers, and anyone supporting a family navigating the lifelong impact of HIE. Dr. Brown's Medical: https://www.drbrownsmedical.com Our NICU Roadmap: A Comprehensive NICU Journal: https://empoweringnicuparents.com/nicujournal/ NICU Mama Hats: https://empoweringnicuparents.com/hats/ NICU Milestone Cards: https://empoweringnicuparents.com/nicuproducts/ Newborn Holiday Cards: https://empoweringnicuparents.com/shop/ Empowering NICU Parents Show Notes: https://empoweringnicuparents.com/shownotes/ Episode 68 Show Notes: https://empoweringnicuparents.com/episode68 Empowering NICU Parents Instagram: https://www.instagram.com/empoweringnicuparents/ Empowering NICU Parents FB Group: https://www.facebook.com/groups/empoweringnicuparents Pinterest Page: https://pin.it/36MJjmH

Story at-a-glance Ischemic strokes block blood flow to brain cells, causing damage through three distinct cell death mechanisms, with iron overload playing a key role Excess iron accumulation during strokes accelerates cell death, functioning like "gasoline on a fire" and worsening brain damage significantly New research shows targeting iron-related cell death could lead to better stroke treatments that protect more brain cells from damage A simple blood test called serum ferritin measures your iron stores. Keeping levels below 100 ng/mL, ideally between 20 and 40 ng/mL, helps protect your brain Regular blood donation (two to four times yearly) is an effective strategy to manage iron levels and reduce stroke risk and severity

With Justyna Sokolska, Institute of Heart Diseases, Wroclaw Medical University, Wroclaw - Poland, and Maja Cikes, University of Zagreb School of Medicine, Head at the Unit for Heart Failure and Mechanical Circulatory Support, Department of Cardiovascular Diseases, University Hospital Center, Zagreb - Croatia. In this episode of HFA CardioTalk, Justyna Sokolska interviews Maja Cikes on the challenges in management of long-term left ventricular assist device in patients with advanced heart failure. The discussion emphasizes the importance of selecting appropriate patients at the optimal time, examines the adverse events and highlights major ongoing clinical trials.  Recommended readings:  Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial, Mehra MR, et al. JAMA. 2023 Dec 12;330(22):2171-81  Trends and Outcomes of Left Ventricular Assist Device Therapy: JACC Focus Seminar, Varshney AS, et al. J Am Coll Cardiol 2022 Mar 22;79(11):1092-1107 Cardiac implantable electronic devices with a defibrillator component and all-cause mortality in left ventricular assist device carriers: results from the PCHF-VAD registry, Cikes M, et al. Eur J Heart Fail 2019 Sep;21(9):1129-41 A Fully Magnetically Levitated Left Ventricular Assist Device — Final Report, Mehra MR, et al. N Engl J Med 2019 Apr 25;380(17):1618-27 This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

See all the Healthcasts at https://www.biobalancehealth.com/healthcast-blog I am not sure if you play THE “WHAT'S THE DISEASE THAT I DON'T WANT TO HAVE GAME with yourself, but since I am a doctor I have spent a lot of time thinking about what diseases I do not want! I started my list in medical school when I witnessed what certain diseases can do to your life.  Medicine has many cures and treatments, yet some diseases that are treated still can negatively change your life forever. Even though losing a limb and amputation were at the top of my list there is one disease that tops my list.  Of course, I also have under stroke the usual scary situations like paralysis, or having an incapacitating heart attack that prevents an individual from taking care of himself or herself. However, my most feared diagnosis is having a STROKE! You may not fully comprehend how a stroke can change your life, but it can affect your speech, your ability to move, to think, to go places, to have a sense of humor, to write and communicate, even to have a sexual relationship with your loved one. A stroke essentially can take away your ability to be the person you have always been, AND it requires that someone must become your caretaker.  That helplessness is something I am most afraid of….We all have our personal fears, but whether you fear having a stroke or not, you should  try your hardest to avoid having one! DEFINITION: a stoke is a medical emergency that occurs when blood flow to the brain is  blocked or a blood vessel bursts. This can damage or kill parts of the brain, which can lead to long-term disability, brain damage, or even death.  This can cause s a loss of function, physical, mental, and  emotional, and loss of one or more of the senses like sensation, speech, sight, hearing and  taste and smell! In my practice at BioBalance Health we always work with our patients to prevent them having a stroke and or heart attack. These two conditions are the biggest villains that steal the joy of our “golden years” from us.  From the start of my BioBalance Health practice, I have incorporated  healthy diet training, exercise options and encouragement, how and what to take to supplement my patients' diet and how to outsmart their genetic makeup so they can be healthier than their parents. All of these lifestyle changes can decrease the risk of stroke and heart attack in a person. So what is it like to have a stroke? First let's go over what symptoms are typical of someone having a stroke. The symptoms of a stroke are multiple, and a person might not have all of them. Weakness on one side of the body Facial drooping on one side of the face Dizziness Numbness Loss of balance Sudden loss of vision. Trouble making sense when speaking Trouble talking, reading or understanding Sudden nausea and vomiting Brief loss of consciousness such as fainting, seizures, confusion, or coma. When someone has one or more of these symptoms it is an emergency, and you should call 911, then start asking the patient to open their eyes, smile, raise both arms and hold them up. Ask them to talk to see if their speech is impaired. Your findings will be helpful to the EMTs who come to the scene. An event is called a stroke, when there is a deficit in physical or mental function and that deficit continues and doesn't go away.  If it the symptoms completely resolve, it is called a TIA- a transient Ischemic attack. It is a warning to see a doctor and make sure you don't have a stroke in the future and it is a wakeup call to stop all poor lifestyle choices.   PREVENTING A STROKE: This last month, the American Heart and Stroke prevention Association released new Guidelines on how to prevent a stroke.  I think talking about the risk factors for stroke and discussing how to prevent having one, is worthy of discussion. Recently the medical guidelines for stroke prevention have been revised, and even though I think a few more things should have been included, the fact that they made the first change in the guidelines in 10 years is a first step. Here is what they advise all people who are aging should do.   #1 See your internal medicine or Family physician regularly, at least yearly #2. Stop sedentary behavior—walk/exercise/ do Yoga, just get out of the chair for the majority of your day! #3. If you are diabetic, they advocate going on Ozempic/Mounjaro to lose weight—that will lower your risk of a stroke, and heart attack.. #4 If you are hypertensive, take your BP medicine every day #5 Follow these lifestyle changes called Life's Essential 8: Your behavior and lifestyle put you at risk for having a stroke:    Healthy diet, low carb Mediterranean diet, no junk food!  Physical activity every day  Achieve a healthy weight,  Make sure your sleep is restful  Stop use of tobacco products, No smoking or vaping  Achieve healthy levels of blood glucose, and blood pressure.  Don't drink more than one 4 oz glass of wine a day  I add these recommendations to theirs for the care of my patients:   Drink ½ your weight in water every day Wat at least half your weight in grams of protein a day Get a Cardiac calcium scan to see if you have arterial plaque. If you do have plaque (arteriosclerosis) then you are at risk for stroke as well. See a cardiologist to be treated preventatively and tested. Option other than a cardiac calcium scan, get a carotid ultrasound to make sure you don't have plaque in the neck vessels that lead to your brain.. Make sure your Homocysteine level is normal (

Dr. Drew Carey speaks with Dr. Tongalp H. Tezel on his study comparing patients with nonarteritic ischemic optic neuropathy (NAION) with healthy non-NAION patients with crowded discs and noncrowded optic discs. From his Ophthalmology article, “Vitreopapillary Findings in Nonarteritic Ischemic Optic Neuropathy versus Healthy Eyes.” Vitreopapillary Findings in Nonarteritic Ischemic Optic Neuropathy versus Healthy Eyes. Hondur, Ahmet M. et al. Ophthalmology, Volume 132, Issue 3, 327 – 334 CALL FOR ABSTRACTS! Now accepting paper, poster, and video submissions through April 8. Imagine presenting at AAO 2025; learn more and submit yours at aao.org/pod25

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Significance of Coronary Artery Calcifications and Ischemic Electrocardiographic Changes Among Patients Undergoing Myocardial Perfusion Imaging

With Robert M.A. van der Boon, Erasmus Medical Center, Rotterdam - The Netherlands, and Anuradha Lala, Mount Sinai Fuster Heart Hospital, New York City - USA. In this episode of HFA Cardio talk, we dive into how factors like sex, socio-economics status and ethnicity shape the way heart failure presents and progresses in different populations. We'll discuss why recognizing these differences is critical for accurate diagnosis and effective treatment and highlight practical steps clinicians can take to close the gaps in prevention and care. Papers: https://onlinelibrary.wiley.com/doi/10.1002/ejhf.2534 https://academic.oup.com/eurheartj/article/40/47/3859/5652224?login=true https://www.sciencedirect.com/science/article/pii/S1071916421004322?via%3Dihub https://www.sciencedirect.com/science/article/pii/S0002914922010074?via%3Dihub https://www.sciencedirect.com/science/article/pii/S2468266719301082?via%3Dihub https://journals.lww.com/co-cardiology/fulltext/2021/05000/racial_and_ethnic_disparities_in_heart_failure_.12.aspx https://onlinelibrary.wiley.com/doi/10.1002/ehf2.14986   This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

With Henrique Arfsten, Medical University of Vienna, Vienna - Austria and Alexandre Mebazza, Hospital Lariboisiere, Paris - France.  In this episode of HFA CardioTalk, Henrike Arfsten and  Alexandre Mebazaa discuss the importance of rapid initiation and titration of guideline-directed medical heart failure therapy. A focus will be on data from the STRONG-HF trial, which demonstrated safety and efficacy of rapid up-titration following an acute heart failure event. The trial was even stopped early as the benefits of the intensive treatment strategy were overwhelming. Moreover, specific questions are raised, such as the right time to start therapy and how to deal with possible side effects. Mebazaa A, et al. Lancet 2022 Dec 3;400(10367):1938-52 Biegus J, et al. Heart Fail Rev 2024 Sep;29(5):1065-1077 McDonagh TA, et al. Eur J Heart Fail 2022 Jan;24(1):4-131 McDonagh TA, et al. Eur J Heart Fail 2024 Jan;26(1):5-17 This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/trade-off-ischemicthrombotic-vs-bleeding/32297/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous thromboembolism (VTE). This makes our understanding and implementation of new findings and clinical trial outcomes that much more important as we develop effective, personalized treatment plans for our patients. Tune in to our micro learning course to make sure you're up to date and providing the care your patients deserve.

With Novi Yanti Sari, Siloam Hospitals, Jakarta - Indonesia, and Mark Petrie, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow - UK. In this episode of the HFA podcast series, we explore the complex relationship between obesity and heart failure, discussing challenges, management strategies, and the latest therapies, while emphasising the importance of integrated care in improving clinical outcomes. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of an unrestricted financial support. The discussion has not been influenced in any way by its sponsor.

In this episode of Autism for Badass Moms, we sit down with Allysa Parker, a dedicated Certified Dental Assistant and fierce advocate for her 6-year-old son, Julian. Julian was diagnosed with Hypoxic Ischemic Encephalopathy (H.I.E.) just two days after birth and later received an Autism diagnosis at 4.5 years old. Navigating these diagnoses has been an emotional rollercoaster for Allysa, bringing moments of helplessness and anxiety. But through it all, she has remained committed to ensuring Julian experiences the world to the fullest. Now, Allysa is using her journey to empower other moms, sharing her insights on H.I.E. and Autism while building a community of support and encouragement. Tune in to hear Allysa's incredible journey. Follow her journey on Instagram: https://www.instagram.com/lovely.loveable.leo/ Don't forget to subscribe and stay tuned for more empowering stories like Allysa's. Follow Us: Instagram: https://www.instagram.com/theabmpodcast/ Facebook: https://www.facebook.com/profile.php?id=100095054651586

With Jasper Brugts, Erasmus Medical Center Rotterdam, Rotterdam - The Netherlands and Floran Sahiti, University Hospital Würzburg and Comprehensive Heart Failure Center Würzburg, Würzburg - Germany. In this episode of the HFA Podcast Series, we will discuss telemonitoring in general, with a main focus on invasive monitoring in heart failure, the current evidence, and the advantages and disadvantages of the systems. This 2025 HFA Cardio Talk podcast series is supported by Bayer AG in the form of unrestricted financial support. The discussion has not been influenced in any way by its sponsors.

In this episode of RCP medicine podcast, Dr Zeina Al-Matlik is joined by Dr John Williamson, a consultant Neurologist and Stroke Physician working in Liverpool,  to discuss one of the leading causes worldwide for disability - Strokes. Whether you are a healthcare provider, caregiver, or a stroke survivor, this podcast covers everything you need to know about the vital ins and outs of stroke. This episode unpacks essential topics such as recognizing the warning signs of strokes and acting FAST, ( Face, Arm, Slurred speech, Time - acronym used for identification of potential stroke), understanding the difference between TIAs ( Transient Ischemic Attacks) and Ischemic and haemorrhagic strokes and their managements, prevention of strokes including lifestyle and medical modifications of risk factors, and finally discussing common Stroke mimics and how to recognize them. Listeners will also get a chance to explore the latest breakthrough advancements and guidelines in stroke research and treatments such as life saving thrombolysis - also known as clot busting medication and thrombectomies - whereby a catheter is inserted into blood vessel to help retrieve and remove clots.This episode is designed to educate, empower, and provide practical tips for both healthcare providers and patients to spread awareness, understand strokes and take prompt action to improve outcomes as Time is brain.

With Daniella Motta da Costa Dan, University of São Paulo - Brazil, and Marianna Adamo, University of Brescia - Italy. In this episode of HFA CardioTalk, Daniella Motta interviews Marianna Adamo on the controversies, consensus, and challenges surrounding revascularization in ischemic heart failure. The discussion highlights major clinical trials, emphasizes the importance of selecting appropriate patients, and examines the risks and benefits of revascularization in this context. Lastly, they address key updates from the latest ESC guidelines This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

Sandra Narayanan, MD, Vascular Neurologist and Neurointerventional Surgeon at the Pacific Stroke and Neurovascular Center at Pacific Neuroscience Institute, explains the difference between hemorrhagic and ischemic stroke.The main difference between the two types of stroke is the underlying cause of the brain damage. In ischemic stroke, the damage is caused by a lack of blood supply, while in hemorrhagic stroke, it is caused by bleeding into the brain tissue. Both types of stroke are medical emergencies and require immediate medical attention to prevent further damage and improve outcomes.

Dr. Jahan will educate listeners about ischemic strokes, including their signs and symptoms, and the critical importance of calling 911 as soon as signs of stroke occur. Dr. Jahan will also highlight the expertise of The Division of Interventional Neuroradiology (DINR) team at Long Beach Medical Center, showcasing the latest minimally invasive treatment options available at Long Beach Medical Center's Comprehensive Stroke Center and how the care team provides exceptional care to their patients.

In this episode, Dr. Valentin Fuster reviews an exploratory analysis from the 80s2 trial, which examined CSL 112's impact on ischemic events after acute myocardial infarction. While CSL 112 didn't significantly reduce cardiovascular death or stroke in the short term, the study found promising long-term benefits, suggesting that enhancing cholesterol efflux could be a valuable approach for reducing recurrent ischemic events in high-risk patients.

In this episode, we dive into exercise-induced ischemic colitis—a lesser-known but impactful condition that affects some endurance athletes, including runners, trekkers and cyclists. Join us as we explore what causes this condition, the symptoms to look out for, and how to prevent it from sidelining your activities. We'll discuss why intense exercise can lead to GI issues, share tips on hydration, and offer guidance on recovery if EIIC does strike. Whether you're a seasoned athlete or just getting into endurance sports, this episode will help you keep your gut health on track while pushing your limits.

Dr. Jodie Roberts and Dr. Amra Sakusic discusses the relationship between reversal therapy and ischemic stroke, between duration off anticoagulation and risk of ischemic strokes or systemic embolism. Learn more about the Neurology Practice Current section and fill out the survey now. Show reference: https://survey.alchemer.com/s3/7969148/Practice-Current-When-do-you-start-anticoagulation-therapy-for-patients-with-both-ICH-and-AF https://www.neurology.org/doi/10.1212/WNL.0000000000209664

With Nicolas Verheyen, Medical University of Graz, Graz - Austria, and Lars Kober, Rigshospitalet, Copenhagen University Hospital, Copenhagen - Denmark.  In this episode of HFA CardioTalk, Nicolas Verheyen interviews Lars Kober on controversies in ICD/CRT implantation in non-ischemic cardiomyopathy for primary prevention. They focus in particular on the importance of selecting the right patients, and discuss biomarkers beyond left ventricular ejection fraction that may add value in predicting sudden death risk, and the need of randomized controlled trials with adequate endpoint selection to guide prophylactic ICD implantation. Related scientific paper: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2023 ESC Guidelines for the management of cardiomyopathies Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure 2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC)   This 2024 HFA CardioTalk podcast serie is supported by Novartis in the form of an educational grant. The discussion has not been influenced in any way by its sponsor.

In this episode, Dr. Valentin Fuster discusses a groundbreaking study that evaluates the role of myocardial fibrosis in predicting sudden cardiac death and ventricular arrhythmias in patients with non-ischemic cardiomyopathy. The findings suggest that assessing fibrosis through advanced imaging techniques offers a more accurate risk stratification than the traditional reliance on left ventricular ejection fraction, ultimately refining treatment approaches for at-risk patients.

Ischemic heart disease is a leading cause of morbidity and mortality. While atherosclerotic coronary artery disease (CAD) is the focus of most outpatient and inpatient evaluations for cardiovascular symptoms, up to two thirds of patients suffer from myocardial ischemia with non-obstructive coronary arteries (INOCA). Patients with INOCA have unique symptoms and are more likely to have functional limitation and repeat presentations for cardiovascular evaluation. While there has been increasing recognition of INOCA there is no specific functional status measure, limiting our ability to evaluate the course of illness or effectiveness of therapies. In this presentation, Dr. Samit Shah, interventional cardiologist at Yale New Haven Hospital who recently gave grand rounds recently to the Mayo Clinic Department of Emergency Medicine, reviews the causes of ischemic heart disease, challenges with current symptom assessment, and proposes a new path for better diagnosis and treatment of heart disease.   CONTACTS X - @AlwaysOnEM; @VenkBellamkonda; @SamitShahMD YouTube - @AlwaysOnEM; @VenkBellamkonda Instagram – @AlwaysOnEM; @Venk_like_vancomycin; @ASFinch Email - AlwaysOnEM@gmail.com

ایسکمی انگشتان پا

VISIT US AT ⁠⁠⁠⁠⁠⁠⁠⁠NCLEXHIGHYIELD.COM⁠⁠⁠⁠⁠⁠⁠⁠ No matter where you are in the world, or what your schedule is like, access the entire course at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.NCLEXHighYieldCourse.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  The NCLEX High Yield Podcast was featured on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Top 15 NCLEX Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠! Make sure you ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠JOIN OUR NEW VIP FACEBOOK GROUP!⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://nclexhighyield.com/blogs/news/nclex-high-yield-quick-links⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ A topic that confuses many, but listen to how Dr. Zeeshan breaks this bad boy down! Many people get overwhelmed with all the information that's out there, we keep it simple! Join us weekly for FREE Zoom Sessions and be one of the many REPEAT test takers that passed the exam by spending NO MONEY with NCLEX High Yield! NCLEX High Yield is a Prep Course and Tutoring Company started by Dr. Zeeshan in order to help people pass the NCLEX, whether it's the first time , or like the majority of our students, it's NOT their first time. We keep things simple, show you trends and tips that no one has discovered, and help you on all levels of the exam! Follow us on Instagram: ⁠⁠⁠⁠⁠⁠⁠@NCLEXHighYield ⁠⁠⁠⁠⁠⁠⁠or check out our website www.NCLEXHighYield.com Make sure you join us for our FREE Weekly Zoom Sessions! Every Wednesday 3PM PST / 6PM EST. Subscribe to our newsletter at ⁠⁠⁠⁠⁠⁠⁠⁠⁠nclexhighyield.com⁠⁠⁠⁠⁠⁠ --- Support this podcast: https://podcasters.spotify.com/pod/show/nclexhighyield/support

Interview with Joseph F. Rizzo III, MD, author of Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Hosted by Neil M. Bressler, MD. Related Content: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

Interview with Joseph F. Rizzo III, MD, author of Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. Hosted by Neil M. Bressler, MD. Related Content: Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide

In part two of this two-part series, Dr. Dan Ackerman and Dr. Gaspard Gerschenfeld discuss the differences in treatment between American Stroke Centers and those in France. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209398  

This week we delve into the world of heart failure and transplantation when we review a recent PHTS study assessing the impact of ischemic time on outcomes of pediatric heart transplantation. What is considered to be a long ischemic time and what is the impact on outcomes in the pediatric patient undergoing transplant? Why does it appear as the impact of a longer ischemic time is less associated with graft failure in the present era in comparison to the past? What might be the impact of newer heart perfusion devices used to transport organs for transplant? These are amongst the questions reviewed with Professor of Pediatrics at U. Colorado, Dr. Scott R. Auerbach. DOI: 10.1016/j.healun.2024.03.002

Dr. Dan Ackerman and Dr. Gaspard Gerschenfeld discuss the efficacy and safety of both thrombolytics in patients with large ischemic core.  Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000209398  

Dr. Dan Ackerman talks with Dr. Gaspard Gerschenfeld about the efficacy and safety of both thrombolytics in patients with large ischemic core. Read the related article in Neurology.  Disclosures can be found at Neurology.org.

Cardiac - Ischemic MR Update (Korri Hershenhouse & Robert Michler)

In this episode, we discuss treatment of acute ischemic priapism, including some updates from the American Urological Association.    Show notes and references: FOAMcast.org

Audio Commentary by Dr. Valentin Fuster, Emeritus Editor in Chief

We will continue our discussion on ischemic episodes with a focus on ischemic colitis. We will examine what disrupts blood flow to the colon, leading to symptoms such as cramping abdominal pain, bloody diarrhea, and urgency to defecate. We will delve into risk factors, including underlying vascular disease, extreme exercise, and in some cases, colonoscopies. A thorough medical history and physical examination, along with an x-ray to check for any free air, are essential. We will also discuss various treatments depending on the severity of the condition. Join Dr. Niket Sonpal for this gut checkup. June 24, 2024 — Do you work in primary care medicine? Primary Care Medicine Essentials is our brand new program specifically designed for primary care providers to increase their core medical knowledge & improve patient flow optimization. Learn more here: Primary Care Essentials —

In this episode, listen to our editorial apprentice, Dr. Eric Peeples describe the scope and importance of our collection on neonatal encephalopathy and hypoxic-ischemic encephalopathy.Visit the collection here: Neonatal Encephalopathy and Hypoxic Ischemic Encephalopathy (nature.com) Hosted on Acast. See acast.com/privacy for more information.

Commentary by Dr. Valentin Fuster

Commentary by Dr. Valentin Fuster

CardioNerds, Dr. Richard Ferraro and Dr. Dan ambinder join Dr. Li Pang, Dr. Emily Hendricks, and Dr. Bei Jiang from West Virginia University to discuss the following case that features apical obliteration with biventricular thrombus. Dr. Christopher Bianco provides the Expert CardioNerd Perspectives & Review (E-CPR) for this episode. Audio editing by CardioNerds Academy Intern, student doctor Tina Reddy. A 37-year-old Caucasian man with a history of tobacco smoking and hypertension who presented with chest pain and elevated troponin was admitted for non-ST elevation myocardial infarction (NSTEMI). Ischemic evaluation with an invasive coronary angiogram was negative. He was treated as NSTEMI and scheduled for outpatient cardiac MRI (CMR). The patient came back 2 months later with right arm weakness and confusion and was found to have an embolic stroke. Labs showed positive troponin with a flat trend and hypereosinophilia. Transthoracic echocardiogram (TTE) showed obliteration of LV and RV apex with thrombus and reduced LV systolic function. CMR was consistent with myocarditis with biventricular thrombus. The patient was started on corticosteroids and warfarin. Hypereosinophilia workup was positive for PDGFRA alpha rearrangement. He was diagnosed with primary hypereosinophila syndrome. Imatinib was initiated. The patient was followed up with the hematology clinic, achieved a complete hematologic response with normalized cell count, and remained free from any cardiovascular event at the 8-month follow-up. US Cardiology Review is now the official journal of CardioNerds! Submit your manuscript here. CardioNerds Case Reports PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Case Media Pearls - Apical Obliteration with Biventricular Thrombus Cardiac MRI is a valuable test for patients presenting with myocardial infarction with non-obstructive coronary arteries (MINOCA). Obliterated apex with apical thrombus on TTE with hypereosinophilia should raise high suspicion for eosinophilic myocarditis. Initiation of corticosteroids is the first-line treatment for eosinophilic myocarditis, which is associated with lower mortality in patients with myocarditis. For other potential complications, such as heart failure, intracardiac thrombus, arrhythmia, and pericardial effusion, the standard of care for each disorder is recommended. Hypereosinophilia can be seen in parasitic infections, vasculitis, asthma, allergy, hematological malignancies, and as a primary disorder. Show Notes - Apical Obliteration with Biventricular Thrombus What is the differential diagnosis for patients with elevated troponin and nonobstructive CAD? The occurrence of acute myocardial infarction (AMI) without significant CAD was reported 80 years ago. However, the term MINOCA (myocardial infarction with non-obstructive coronary arteries) has only been used recently to describe these patients. It involves ischemic and nonischemic etiologies. First, overlooked ischemic etiologies need to be ruled out by reconciling the angiogram images such as spontaneous coronary artery dissection (SCAD) and plaque disruption. Intracoronary imaging, such as intravascular ultrasound (IVUS) or optical coherence tomography (OCT), may be applied to evaluate for SCAD and subtypes of plaque disruption when indicated.  The investigation continues with nonischemic causes such as stress cardiomyopathy, myocarditis, pulmonary embolism, demand ischemia from sepsis, anemia, chest trauma, heart failure exacerbation, arrhythmia, and stroke. The diagnosis of MINOCA is established when it fulfills the following criteria: First, it is AMI by the Fourth Universal Definition; Second, less than 50% of stenotic lesion on angiogram; Third, there is no alternate diagnosis.

Ischemic Changes by Albuquerque Fire Rescue

CSL112 (Apolipoprotein A-I) Infusions And Cardiovascular Outcomes In Patients With Acute Myocardial Infarction (ApoA-I Event Reducing In Ischemic Syndromes II (AEGIS-II) Trial): Primary Trial Results

In this milestone 20th episode, we delve into the critical topic of stroke, featuring a special guest, Midnight Med. Join us as we uncover the high-yield features of stroke, covering both ischemic and hemorrhagic strokes. Midnight Med, renowned for their insightful medical content, takes us on an in-depth exploration of ischemic stroke, highlighting key aspects, diagnostic approaches, and management strategies. Tune in as they share their expertise and provide valuable insights. Meanwhile, we tackle the complexities of hemorrhagic stroke, examining its distinct characteristics, risk factors, and treatment modalities. Don't miss out on this exciting episode! Check out Midnight Med's Instagram @midnightmed1200, and give us a follow at 5.min.medicine if you haven't already. Give their Spotify a follow: Midnight Med Podcast. Access to all podcast scripts will be coming soon FREE to our new website (also featuring a shop for medical students). Listen now and empower yourself with knowledge to better understand and manage stroke.

Today we give you our second pediatric clinical case with Dr. Sakina Butt.  This time she talks about hypoxic-ischemic injury and low Apgar scores in infants and young children, or “littles” as she endearingly refers to them. Show notes are available at www.NavNeuro.com/129 _________________ If you'd like to support the show, here are a few easy ways: 1) Get APA-approved CE credits for listening to select episodes: www.NavNeuro.com/INS  2) Tell your friends and colleagues about it 3) Subscribe (free) and leave an Apple Podcasts rating/review: www.NavNeuro.com/itunes 4) Check out our book Becoming a Neuropsychologist, and leave it an Amazon rating   Thanks for listening, and join us next time as we continue to navigate the brain and behavior! [Note: This podcast and all linked content is intended for general educational purposes only and does not constitute the practice of psychology or any other professional healthcare advice and services. No professional relationship is formed between hosts and listeners. All content is to be used at listeners' own risk. Users should always seek appropriate medical and psychological care from their licensed healthcare provider.]

In our next episode for the Liver Series, we will discuss Ischemic Hepatitis, a condition that occurs when the liver does not receive enough blood flow. This can be caused by a variety of factore, including heart failure, sepsis and shock. Join Dr. Niket Sonpal as he discusses the symptoms of Ischemic Hepatitis, which can include jaundice, fatigue, nausea, and vomiting. He will also go over the diagnosis and treatments for your patient. August 14, 2023 — Never pay for another course, workshop or seminar again. Become a member and get full access to every resource we've ever made. You'll also get 50 CAT 1 CMEs every calendar year as part of your membership. Click the link to learn more about becoming a member: Medgeeks All Access — Do you work in primary care medicine? Primary Care Medicine Essentials is our brand new program specifically designed for primary care providers to increase their core medical knowledge & improve patient flow optimization. Learn more here: Primary Care Essentials —

A viral documentary says a "whole foods plant-based diet" will prevent heart disease and cure cancer. But once we look into the MEAT of the matter will we find factual CREAM of the crop or will we  cry FOWL? (we're so sorry)Thanks to Katherine Flegal for helping Mike with this episode!Support us:Hear bonus episodes on PatreonDonate on PayPalGet Maintenance Phase T-shirts, stickers and moreBuy Aubrey's bookListen to Mike's other podcastLinks!Health effects associated with consumption of unprocessed red meat: a Burden of Proof studyUnprocessed Red Meat and Processed Meat Consumption: Dietary Guideline Recommendations From the Nutritional Recommendations (NutriRECS) ConsortiumPresent status of the aflatoxin situation in the PhilippinesThe role of natural consequences in the changing death patternsDietary Protein and Amino Acids in Vegetarian Diets—A ReviewQuality of Plant-Based Diet and Risk of Total, Ischemic, and Hemorrhagic StrokeParachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trialDo We Really Know What Makes Us Healthy?Observational evidence does not necessarily imply causationThe Problem with Observational Studies (Epidemiology)Vegetarian Diet Patterns and Chronic Disease Risk: What We Know and What We Don'tThe rise, the fall and the renaissance of vitamin EThanks to Doctor Dreamchip for our lovely theme song!Support the show